Switch theme
Sign up to access all valuation multiples
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
1999
15.8K+
LTM Revenue $5.6B
LTM EBITDA $1.8B
$42.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Edwards Lifesciences has a last 12-month revenue (LTM) of $5.6B and a last 12-month EBITDA of $1.8B.
In the most recent fiscal year, Edwards Lifesciences achieved revenue of $5.4B and an EBITDA of $1.7B.
Edwards Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Edwards Lifesciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.6B | XXX | $5.4B | XXX | XXX | XXX |
| Gross Profit | $4.4B | XXX | $4.3B | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $1.8B | XXX | $1.7B | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $1.6B | XXX | $1.5B | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $1.5B | XXX | $4.2B | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 77% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Edwards Lifesciences's stock price is $78.
Edwards Lifesciences has current market cap of $45.9B, and EV of $42.7B.
See Edwards Lifesciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $42.7B | $45.9B | XXX | XXX | XXX | XXX | $2.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Edwards Lifesciences has market cap of $45.9B and EV of $42.7B.
Edwards Lifesciences's trades at 7.8x EV/Revenue multiple, and 24.8x EV/EBITDA.
Equity research analysts estimate Edwards Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Edwards Lifesciences has a P/E ratio of 31.5x.
See valuation multiples for Edwards Lifesciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45.9B | XXX | $45.9B | XXX | XXX | XXX |
| EV (current) | $42.7B | XXX | $42.7B | XXX | XXX | XXX |
| EV/Revenue | 7.6x | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBITDA | 24.4x | XXX | 24.8x | XXX | XXX | XXX |
| EV/EBIT | 26.5x | XXX | 28.8x | XXX | XXX | XXX |
| EV/Gross Profit | 9.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 31.5x | XXX | 11.0x | XXX | XXX | XXX |
| EV/FCF | 32.9x | XXX | 164.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEdwards Lifesciences's last 12 month revenue growth is 9%
Edwards Lifesciences's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Edwards Lifesciences's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Edwards Lifesciences's rule of X is 54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Edwards Lifesciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Edwards Lifesciences acquired XXX companies to date.
Last acquisition by Edwards Lifesciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Edwards Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Edwards Lifesciences founded? | Edwards Lifesciences was founded in 1999. |
| Where is Edwards Lifesciences headquartered? | Edwards Lifesciences is headquartered in United States of America. |
| How many employees does Edwards Lifesciences have? | As of today, Edwards Lifesciences has 15.8K+ employees. |
| Who is the CEO of Edwards Lifesciences? | Edwards Lifesciences's CEO is Mr. Bernard J. Zovighian. |
| Is Edwards Lifesciences publicy listed? | Yes, Edwards Lifesciences is a public company listed on NYS. |
| What is the stock symbol of Edwards Lifesciences? | Edwards Lifesciences trades under EW ticker. |
| When did Edwards Lifesciences go public? | Edwards Lifesciences went public in 2000. |
| Who are competitors of Edwards Lifesciences? | Similar companies to Edwards Lifesciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Edwards Lifesciences? | Edwards Lifesciences's current market cap is $45.9B |
| What is the current revenue of Edwards Lifesciences? | Edwards Lifesciences's last 12 months revenue is $5.6B. |
| What is the current revenue growth of Edwards Lifesciences? | Edwards Lifesciences revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Edwards Lifesciences? | Current revenue multiple of Edwards Lifesciences is 7.6x. |
| Is Edwards Lifesciences profitable? | Yes, Edwards Lifesciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Edwards Lifesciences? | Edwards Lifesciences's last 12 months EBITDA is $1.8B. |
| What is Edwards Lifesciences's EBITDA margin? | Edwards Lifesciences's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Edwards Lifesciences? | Current EBITDA multiple of Edwards Lifesciences is 24.4x. |
| What is the current FCF of Edwards Lifesciences? | Edwards Lifesciences's last 12 months FCF is $1.3B. |
| What is Edwards Lifesciences's FCF margin? | Edwards Lifesciences's last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of Edwards Lifesciences? | Current FCF multiple of Edwards Lifesciences is 32.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
